Evidence map›Paper›PMID 25856750›Full record

ArticleCell host & microbe2015

Calnexin bridges the gap toward a pan-fungal vaccine.

Amariliz Rivera, Tobias M Hohl

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Cell host & microbe, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Immunity to fungi in the lung.Seminars in immunology · 2023
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Amariliz RiveraCenter for Immunity and Inflammation, New Jersey Medical School, Rutgers University, Newark, NJ 07103, USA. Electronic address: riveraam@njms.rutgers.edu.
Tobias M HohlInfectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA. Electronic address: hohlt@mskcc.org.
Memorial Sloan Kettering Cancer Center · USRutgers, The State University of New Jersey · US

Funding

INITIATION OF THE IMMUNE RESPONSE TO ASPERGILLUS FUMIGATUSR01AI093808 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI HOHL, TOBIAS M · 2011 to 2020
$4.9M
INITIATION OF THE IMMUNE RESPONSE TO ASPERGILLUS FUMIGATUSR37AI093808 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI TOBIAS M HOHL · 2021 to 2026
$4.2M
Dissection of Macrophage Antifungal Activity against Aspergillus fumigatusR21AI105617 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI HOHL, TOBIAS M · 2013 to 2014
$473k
Role of CCR2+ monocytes and Mo-DCs in defense against IA and GVHD developmentR21CA167238 · NCI · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI RIVERA, AMARILIZ · 2013 to 2014
$375k
CD4+ T cells in Invasive AspergillosisK22CA160874 · NCI · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI RIVERA, AMARILIZ · 2011 to 2012
$372k
NCI NIH HHS K22 CA160874NCI NIH HHS R21 CA167238NCI NIH HHS R21 CA167238-01A1NIAID NIH HHS R21 AI105617NIAID NIH HHS R37 AI093808
6 · The paper itself

Abstract

Vaccines are needed to combat the global rise in fungal diseases. In this issue of Cell Host & Microbe, Wüthrich et al. (2015) identify calnexin as a target of antigen-specific CD4 T cell responses against multiple fungal pathogens. This study illustrates that a conserved epitope triggers convergent cell-mediated immune responses to confer heterologous antifungal immunity.

Indexed as

AnimalsAntigens, FungalAscomycotaCalnexinCD4-Positive T-LymphocytesCell ProliferationEpitopesAntigens, FungalCalnexinEpitopes

Identifiers

PMID25856750
OpenAlexW2088346809

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.